Global Opthalmic Pharmaceutical Drugs 麻豆原创 Research Report 2023

Publication ID:

PB504239044

Publication Date:

April 11, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Ophthalmic drugs are extensively used to treat glaucoma, cataract, diabetic retinopathy, and other ophthalmic disorders. Introduction of novel ocular drug delivery approaches in the market has driven the manufacturers to develop innovative therapeutic approaches for the treatment of ophthalmic disorders.
Highlights
The global Opthalmic Pharmaceutical Drugs market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Opthalmic Pharmaceutical Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Opthalmic Pharmaceutical Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Opthalmic Pharmaceutical Drugs include Johnson & Johnson, Carl-Zeiss, Ellex Medical Lasers, Essilor International, Hoya Corporation, Insight Vision, Nidek, Novagali Pharma and Topcon Corporation, etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Opthalmic Pharmaceutical Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Opthalmic Pharmaceutical Drugs.
The Opthalmic Pharmaceutical Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Opthalmic Pharmaceutical Drugs market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Opthalmic Pharmaceutical Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Johnson & Johnson
Carl-Zeiss
Ellex Medical Lasers
Essilor International
Hoya Corporation
Insight Vision
Nidek
Novagali Pharma
Topcon Corporation
Ziemer Ophthalmic Systems
Segment by Type
Anti-glaucoma
Anti-infection
Anti-inflammatory
Anti-allergy
Segment by Application
Hospital Pharmacies
Drug Stores
Online Pharmacies
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Opthalmic Pharmaceutical Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Opthalmic Pharmaceutical Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Opthalmic Pharmaceutical Drugs 麻豆原创 Overview
1.1 Product Overview and Scope of Opthalmic Pharmaceutical Drugs
1.2 Opthalmic Pharmaceutical Drugs Segment by Type
1.2.1 Global Opthalmic Pharmaceutical Drugs 麻豆原创 Value Comparison by Type (2023-2029)
1.2.2 Anti-glaucoma
1.2.3 Anti-infection
1.2.4 Anti-inflammatory
1.2.5 Anti-allergy
1.3 Opthalmic Pharmaceutical Drugs Segment by Application
1.3.1 Global Opthalmic Pharmaceutical Drugs 麻豆原创 Value by Application: (2023-2029)
1.3.2 Hospital Pharmacies
1.3.3 Drug Stores
1.3.4 Online Pharmacies
1.3.5 Others
1.4 Global Opthalmic Pharmaceutical Drugs 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Opthalmic Pharmaceutical Drugs Revenue 2018-2029
1.4.2 Global Opthalmic Pharmaceutical Drugs Sales 2018-2029
1.4.3 Global Opthalmic Pharmaceutical Drugs 麻豆原创 Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Opthalmic Pharmaceutical Drugs 麻豆原创 Competition by Manufacturers
2.1 Global Opthalmic Pharmaceutical Drugs Sales 麻豆原创 Share by Manufacturers (2018-2023)
2.2 Global Opthalmic Pharmaceutical Drugs Revenue 麻豆原创 Share by Manufacturers (2018-2023)
2.3 Global Opthalmic Pharmaceutical Drugs Average Price by Manufacturers (2018-2023)
2.4 Global Opthalmic Pharmaceutical Drugs Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Opthalmic Pharmaceutical Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Opthalmic Pharmaceutical Drugs, Product Type & Application
2.7 Opthalmic Pharmaceutical Drugs 麻豆原创 Competitive Situation and Trends
2.7.1 Opthalmic Pharmaceutical Drugs 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Opthalmic Pharmaceutical Drugs Players 麻豆原创 Share by Revenue
2.7.3 Global Opthalmic Pharmaceutical Drugs 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Opthalmic Pharmaceutical Drugs Retrospective 麻豆原创 Scenario by Region
3.1 Global Opthalmic Pharmaceutical Drugs 麻豆原创 Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Opthalmic Pharmaceutical Drugs Global Opthalmic Pharmaceutical Drugs Sales by Region: 2018-2029
3.2.1 Global Opthalmic Pharmaceutical Drugs Sales by Region: 2018-2023
3.2.2 Global Opthalmic Pharmaceutical Drugs Sales by Region: 2024-2029
3.3 Global Opthalmic Pharmaceutical Drugs Global Opthalmic Pharmaceutical Drugs Revenue by Region: 2018-2029
3.3.1 Global Opthalmic Pharmaceutical Drugs Revenue by Region: 2018-2023
3.3.2 Global Opthalmic Pharmaceutical Drugs Revenue by Region: 2024-2029
3.4 North America Opthalmic Pharmaceutical Drugs 麻豆原创 Facts & Figures by Country
3.4.1 North America Opthalmic Pharmaceutical Drugs 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Opthalmic Pharmaceutical Drugs Sales by Country (2018-2029)
3.4.3 North America Opthalmic Pharmaceutical Drugs Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Opthalmic Pharmaceutical Drugs 麻豆原创 Facts & Figures by Country
3.5.1 Europe Opthalmic Pharmaceutical Drugs 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Opthalmic Pharmaceutical Drugs Sales by Country (2018-2029)
3.5.3 Europe Opthalmic Pharmaceutical Drugs Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Opthalmic Pharmaceutical Drugs 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Opthalmic Pharmaceutical Drugs 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Opthalmic Pharmaceutical Drugs Sales by Country (2018-2029)
3.6.3 Asia Pacific Opthalmic Pharmaceutical Drugs Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Opthalmic Pharmaceutical Drugs 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Opthalmic Pharmaceutical Drugs 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Opthalmic Pharmaceutical Drugs Sales by Country (2018-2029)
3.7.3 Latin America Opthalmic Pharmaceutical Drugs Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Opthalmic Pharmaceutical Drugs 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Opthalmic Pharmaceutical Drugs 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Opthalmic Pharmaceutical Drugs Sales by Country (2018-2029)
3.8.3 Middle East and Africa Opthalmic Pharmaceutical Drugs Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Opthalmic Pharmaceutical Drugs Sales by Type (2018-2029)
4.1.1 Global Opthalmic Pharmaceutical Drugs Sales by Type (2018-2023)
4.1.2 Global Opthalmic Pharmaceutical Drugs Sales by Type (2024-2029)
4.1.3 Global Opthalmic Pharmaceutical Drugs Sales 麻豆原创 Share by Type (2018-2029)
4.2 Global Opthalmic Pharmaceutical Drugs Revenue by Type (2018-2029)
4.2.1 Global Opthalmic Pharmaceutical Drugs Revenue by Type (2018-2023)
4.2.2 Global Opthalmic Pharmaceutical Drugs Revenue by Type (2024-2029)
4.2.3 Global Opthalmic Pharmaceutical Drugs Revenue 麻豆原创 Share by Type (2018-2029)
4.3 Global Opthalmic Pharmaceutical Drugs Price by Type (2018-2029)
5 Segment by Application
5.1 Global Opthalmic Pharmaceutical Drugs Sales by Application (2018-2029)
5.1.1 Global Opthalmic Pharmaceutical Drugs Sales by Application (2018-2023)
5.1.2 Global Opthalmic Pharmaceutical Drugs Sales by Application (2024-2029)
5.1.3 Global Opthalmic Pharmaceutical Drugs Sales 麻豆原创 Share by Application (2018-2029)
5.2 Global Opthalmic Pharmaceutical Drugs Revenue by Application (2018-2029)
5.2.1 Global Opthalmic Pharmaceutical Drugs Revenue by Application (2018-2023)
5.2.2 Global Opthalmic Pharmaceutical Drugs Revenue by Application (2024-2029)
5.2.3 Global Opthalmic Pharmaceutical Drugs Revenue 麻豆原创 Share by Application (2018-2029)
5.3 Global Opthalmic Pharmaceutical Drugs Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Johnson & Johnson
6.1.1 Johnson & Johnson Corporation Information
6.1.2 Johnson & Johnson Description and Business Overview
6.1.3 Johnson & Johnson Opthalmic Pharmaceutical Drugs Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Johnson & Johnson Opthalmic Pharmaceutical Drugs Product Portfolio
6.1.5 Johnson & Johnson Recent Developments/Updates
6.2 Carl-Zeiss
6.2.1 Carl-Zeiss Corporation Information
6.2.2 Carl-Zeiss Description and Business Overview
6.2.3 Carl-Zeiss Opthalmic Pharmaceutical Drugs Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Carl-Zeiss Opthalmic Pharmaceutical Drugs Product Portfolio
6.2.5 Carl-Zeiss Recent Developments/Updates
6.3 Ellex Medical Lasers
6.3.1 Ellex Medical Lasers Corporation Information
6.3.2 Ellex Medical Lasers Description and Business Overview
6.3.3 Ellex Medical Lasers Opthalmic Pharmaceutical Drugs Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Ellex Medical Lasers Opthalmic Pharmaceutical Drugs Product Portfolio
6.3.5 Ellex Medical Lasers Recent Developments/Updates
6.4 Essilor International
6.4.1 Essilor International Corporation Information
6.4.2 Essilor International Description and Business Overview
6.4.3 Essilor International Opthalmic Pharmaceutical Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Essilor International Opthalmic Pharmaceutical Drugs Product Portfolio
6.4.5 Essilor International Recent Developments/Updates
6.5 Hoya Corporation
6.5.1 Hoya Corporation Corporation Information
6.5.2 Hoya Corporation Description and Business Overview
6.5.3 Hoya Corporation Opthalmic Pharmaceutical Drugs Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Hoya Corporation Opthalmic Pharmaceutical Drugs Product Portfolio
6.5.5 Hoya Corporation Recent Developments/Updates
6.6 Insight Vision
6.6.1 Insight Vision Corporation Information
6.6.2 Insight Vision Description and Business Overview
6.6.3 Insight Vision Opthalmic Pharmaceutical Drugs Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Insight Vision Opthalmic Pharmaceutical Drugs Product Portfolio
6.6.5 Insight Vision Recent Developments/Updates
6.7 Nidek
6.6.1 Nidek Corporation Information
6.6.2 Nidek Description and Business Overview
6.6.3 Nidek Opthalmic Pharmaceutical Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Nidek Opthalmic Pharmaceutical Drugs Product Portfolio
6.7.5 Nidek Recent Developments/Updates
6.8 Novagali Pharma
6.8.1 Novagali Pharma Corporation Information
6.8.2 Novagali Pharma Description and Business Overview
6.8.3 Novagali Pharma Opthalmic Pharmaceutical Drugs Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Novagali Pharma Opthalmic Pharmaceutical Drugs Product Portfolio
6.8.5 Novagali Pharma Recent Developments/Updates
6.9 Topcon Corporation
6.9.1 Topcon Corporation Corporation Information
6.9.2 Topcon Corporation Description and Business Overview
6.9.3 Topcon Corporation Opthalmic Pharmaceutical Drugs Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Topcon Corporation Opthalmic Pharmaceutical Drugs Product Portfolio
6.9.5 Topcon Corporation Recent Developments/Updates
6.10 Ziemer Ophthalmic Systems
6.10.1 Ziemer Ophthalmic Systems Corporation Information
6.10.2 Ziemer Ophthalmic Systems Description and Business Overview
6.10.3 Ziemer Ophthalmic Systems Opthalmic Pharmaceutical Drugs Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Ziemer Ophthalmic Systems Opthalmic Pharmaceutical Drugs Product Portfolio
6.10.5 Ziemer Ophthalmic Systems Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Opthalmic Pharmaceutical Drugs Industry Chain Analysis
7.2 Opthalmic Pharmaceutical Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Opthalmic Pharmaceutical Drugs Production Mode & Process
7.4 Opthalmic Pharmaceutical Drugs Sales and 麻豆原创ing
7.4.1 Opthalmic Pharmaceutical Drugs Sales Channels
7.4.2 Opthalmic Pharmaceutical Drugs Distributors
7.5 Opthalmic Pharmaceutical Drugs Customers
8 Opthalmic Pharmaceutical Drugs 麻豆原创 Dynamics
8.1 Opthalmic Pharmaceutical Drugs Industry Trends
8.2 Opthalmic Pharmaceutical Drugs 麻豆原创 Drivers
8.3 Opthalmic Pharmaceutical Drugs 麻豆原创 Challenges
8.4 Opthalmic Pharmaceutical Drugs 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Johnson & Johnson
Carl-Zeiss
Ellex Medical Lasers
Essilor International
Hoya Corporation
Insight Vision
Nidek
Novagali Pharma
Topcon Corporation
Ziemer Ophthalmic Systems

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.